The quest to cure cancer might sound lofty, but plenty of researchers, scientists advocates and investors are chipping away it all the time. Now, the American Cancer Society is launching a new approach with BrightEdge, a philanthropic impact fund.
It functions like a venture capital firm but with an altruistic goal: To find innovations in cancer treatment and invest in them so they can get to patients sooner.
Bob Crutchfield, managing director of BrightEdge, joined The Show to talk about the venture and why the American Cancer Society wanted to go in this direction.
